IL22 and metabolic disease: In metabolic disorders, the gut microbiota’s capacity to produce indoles is often diminished, resulting in reduced levels of protective molecules, such as GLP-1 and Interleukin-22 (IL-22), and subsequently increased intestinal permeability and hepatic steatosis (Natividad et al., 2018).